Steve Miller - Aug 18, 2022 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Operating Officer
Signature
/s/ Steve Miller
Stock symbol
CPRX
Transactions as of
Aug 18, 2022
Transactions value $
-$1,650,422
Form type
4
Date filed
8/19/2022, 05:03 PM
Previous filing
Feb 16, 2022
Next filing
Sep 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $300K +119K +15.57% $2.53* 880K Aug 18, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$1.61M -119K -13.47% $13.56 762K Aug 18, 2022 Direct F1, F3
transaction CPRX Common stock, par value $0.001 per share Options Exercise $79.5K +31.4K +4.13% $2.53* 793K Aug 18, 2022 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale -$422K -31.4K -3.96% $13.43 762K Aug 18, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Award $0 -119K -7.36% $0.00 1.49M Aug 18, 2022 Common Stock 119K $2.53 Direct F4
transaction CPRX Options to purchase common stock Award $0 -31.4K -2.11% $0.00 1.46M Aug 18, 2022 Common Stock 31.4K $2.53 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold in various lots from $13.37 to $13.66 per share. The listed sales price represents a weighted average price for the shares sold.
F2 Shares were sold in various lots from $13.30 to $13.54 per share. The listed sales price represents a weighted average price for the shares sold.
F3 Shares were sold to cover exercise price of options, tax withholding requirements (if applicable) and for personal reasons. Shares were not sold as a result of any disagreement with the Company and Dr. Miller remains an officer of the Company.
F4 Options vested in three annual tranches beginning on December 30, 2016.